• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Nov 24

Dr Reddy’s Laboratories Ltd has launched an authorised generic version of GlaxoSmithKline’s Imitrex (sumatriptan succinate) tablets in 25mg, 50mg, and 100mg in the US. Dr Reddy’s is the first company to launch the generic version of Imitrex in the US market, according to a company press release. In October 2006, the Hyderabad-based company had settled a patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, which paved the way f or the launch of the product. The specific financial terms and conditions of the settlement were not disclosed. The Imitrex tablets, which are indicated for the acute treatment of migraine in adults, had US sales of $1.29 billion for the 12 month period ending December, 2007, the release added. —

Our Bureau

More Stories on : New Products & Services | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line